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ABSTRACT 
Background: MCM7 is a downstream of HER1 signaling. We examined MCM7, geminin and 
HER1 expression in laryngeal squamous-cell carcinoma (LSCC) patients treated with radiotherapy 
and cetuximab. 
Methods: MCM7, geminin and HER1 were evaluated by immunohistochemistry on 61 LSCC 
patients. The follow-up (median: 32.1 months; range: 2-139) went from the beginning of therapy to  
tumor progression (PFS) and death (OS).  
Results: MCM7, but not geminin, was associated only with HER1 expression, while no association 
was with other clinicopathological characteristics. Patients with MCM7 high - geminin high and 
MCM7 high - geminin low tumor status had a risk of progression 3.1 times and 17.7 times greater, 
respectively than patients with MCM7 low – geminin high tumor status. Tumor site, MCM7 and 
geminin were independent determinants of PFS, while MCM7 was an independent prognostic 
marker of OS. 
Conclusions: MCM7-geminin tumor status may be prognostic for LSCC patients treated with 
cetuximab and radiotherapy. 
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INTRODUCTION 
Minichromosome maintenance proteins (MCM) belong to a family of six highly conserved and 
highly homologous proteins (MCM2-7). MCM protein 2-7 form a functional hexameric complex, 
constituting an important part of the pre-recognition complex of proteins present at DNA replication 
origins during the G1 phase of the cell cycle 
1
.  
MCM proteins show continuous expression patterns during the cell cycle, although they are bound 
to chromatin only in the late mitosis and early G1 phase 
2
. In the course of the S-phase, MCM 
proteins become irreversibly detached from chromatin, assuring that DNA replication takes place 
only once in the cell cycle 
3
. 
MCM proteins represent a reliable marker of cell cycle entry as their expression has been 
demonstrated in cells remaining in the cell cycle, while loss of MCM expression reflects the resting 
state of the cells 
4
. Moreover, MCM proteins are also involved in transcription, chromatin 
remodeling and checkpoint responses 
5
. 
The requirement for MCM proteins in cycling cells but their absence in quiescent cells have led to 
their potential clinical application as markers for cancer screening. 
Dysregulation of MCM family members has been studied in several types of neoplasia in relation to 
important clinico-pathological characteristics and, as cell proliferation markers, they constitute 
diagnostic and prognostic tools of great clinical significance for patient management and survival. 
In particular, MCM7 has been associated with tumorigenesis in various human cancers, including 
oral squamous cell carcinoma, colorectal cancer, ovarian cancer, glioblastoma, and esophageal 
carcinoma 
6
. 
Geminin is thought to be a regulator of the process that inhibits DNA re-replication in the same cell 
cycle. Geminin expression has been shown to be restricted to S, G2 and early M cell-cycle phase 
7
 
and it functions as a protector of genome stability by preventing the untimely binding of MCM 
complex to chromatin during the S phase, the G2 phase and early mitosis 
8
. Therefore, geminin is 
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involved in the regulation of the cell cycle and in keeping genomic integrity. Furthermore, geminin, 
as negative regulator of the MCM loading factor Cdt1 
9
, may be a potential tumor suppressor gene 
10
. 
Geminin expression might complement information obtained from evaluation of MCM labeling, 
giving an indication of cell-cycle rate. In fact, MCM proteins mark all non-quiescent cells, whereas 
geminin identifies the proportion of actively proliferating cells that have entered S-phase, but not 
exited mitosis 
7
. 
The assessment of expression of both MCM7 and geminin may be a promising marker of cell 
proliferation, and it has been related to tumor progression and distant metastases 
6
, but its role as 
biomarker in laryngeal cancer is still need to be clarified. 
Epidermal growth factor receptor (HER1) appears, at present, to be the most reliable molecular 
marker in head and neck squamous cell carcinogenesis, as it is expressed in over 90% of head and 
neck squamous cell carcinomas (SCCs). HER1 over-expression in laryngeal squamous-cell 
carcinoma (LSCC) has been shown to correlate with worse clinical outcome 
11-16
, decreased 
response to radiotherapy, and increased locoregional recurrence following definitive radiotherapy 
17
. 
Cetuximab is an IgG1 monoclonal antibody that exclusively targets EGFR with high affinity, and 
inhibits endogenous ligand binding, thereby blocking receptor dimerization, tyrosine kinase 
phosphorylation, and signal transduction 
18-20
. Furthermore, in-vitro and in-vivo studies have shown 
that there is synergy between cetuximab and radiotherapy with the combination resulting in a 
greater reduction in cellular proliferation than either treatment alone 
21-24
. However, despite initial 
encouraging results of the pivotal trial of the anti-EGFr antibody cetuximab and radiation therapy in 
locally advanced HNSCC patients, demonstrating a significantly improved median time to 
progression, negative disappointing randomized phase III trials data 
25, 
indicate that much more 
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remains to be clarified with regard to EGFR biology and patient selection. In fact at present there is 
not reliable predictor of sensitivity to cetuximab including HER1 expression. 
Recently, it has been proposed that HER1 enhances MCM7 phosphorylation and DNA replication 
through Lyn phosphorylation in human cancer cells thereby raising the possibility that MCM7 is a 
downstream target of HER1 signaling 
26
. Since MCM7 is critical in DNA replication and involved 
in oncogenic signaling pathways, we set out to verify whether the expression of MCM7 and 
geminin in primary LSCC may potentially be used for screening and estimation of prognosis for 
patients who underwent radiotherapy in combination with cetuximab. Moreover, this study was 
site-specific with a series composed exclusively of laryngeal squamous cell carcinomas to reduce 
the biological and clinical heterogeneity associated with different sites of origin in head and neck. 
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MATERIALS AND METHODS 
Patients 
Study design 
From 1998 to 2012, 61 consecutive untreated, newly diagnosed laryngeal squamous cell carcinoma 
(LSCC) patients (age: mean = 65.4 years; median = 65 years; range: 40-86 years) suitable for an 
organ preservation protocol according to International Guidelines (NCCN V2.2014), or, in case of 
T4 any N, refused other therapeutic options, treated definitively with cetuximab (C 225) 
concurrently with radiotherapy at Catholic University Head and Neck Cancer Center were reviewed 
(Institutional Review Tumor Board “SpiderNet”). Eligible patients had untreated, histologically 
confirmed, stage II, III or IV LSCC; Zubrod performance status 0 to 1; age > 18 years; any tobacco 
status; and adequate bone marrow, hepatic, heart, and renal functions. We excluded patients who 
received additional concurrent, induction, or adjuvant systemic therapy; weekly cisplatin; prior HN 
radiotherapy; or primary surgical resection; Histological grading and TNM classification was 
performed according to the recommendations of the International Union Against Cancer. All 
patients underwent a full diagnostic work up including a complete head and neck exam; mirror, 
fiberoptic, and narrow band imaging (NBI)-videoendoscopic examination; representative biopsy; 
chest CT; CT and MRI of larynx and neck; PET/CT for advanced disease, as suggested by NCCN 
guidelines (version 2.2014). After the work-up all cases were staged and discussed by the Tumor 
Board involving at least a medical oncologist, a radiation therapist, and an ENT surgeon. Smoking 
and drinking status were assessed, 23 patients were ex-smokers (37,7%), 6 (9,8%) patients were 
never-smokers, 22 (36%) patients were smokers with a mean of 46 years of tobacco use and in 10 
(16,4%) cases the tobacco use was not known. Current and previous smokers had a mean pack/year 
index of 61,4 (range 6 - 250). Thirty (49,2%) patients were current drinkers and 7 (11,5%) were 
previous drinkers. Fourteen (23%) patients were both drinkers and smokers. Other patient and 
tumor characteristics are listed in table 1.  
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Treatment 
All patients received dental care followed by intensity-modulated radiation therapy (IMRT). We 
delivered 69.96 Gy at 2.12 Gy per fraction to the planning target volume (PTV) encompassing the 
gross tumor volume (GTV), 59.4 Gy at 1.8 Gy per fraction to the PTV of the high-risk clinical 
target volume (CTV), and 54 Gy at 1.64 Gy per fraction to the PVT of the low-risk CTV. The 
GTVs and CTVs were each expanded 3 to 5 mm to generate their respective PTVs. Cetuximab was 
administered at an initial dose of 400 mg/m2 during the week before IMRT and then 250 mg/m2 
per week during radiotherapy with a maximum of 7 additional doses. Toxicity was evaluated 
weekly during therapy using the Common Terminology Criteria for Adverse Events (version 3). 
Adverse events reported as definitely, probably, or possibly related were considered treatment-
related events. During the treatment period the patients were examined weekly with transnasal fiber 
optic laryngoscopy to evaluate the respiratory laryngeal space and swallowing. Patients were 
assessed after the completion of treatment with physical examination, NBI-videolaryngoscopy, 
imaging studies, and, if there was a high suspicion of residual laryngeal disease, endoscopic 
laryngeal examination with biopsy plus a possible salvage surgery (i.e., partial or total 
laryngectomy was performed). Furthermore, if there was residual neck disease, comprehensive 
radical modified neck dissection was also performed. In the follow-up period, CT or MRI imaging 
was performed 8 to 9 weeks after treatment, at 6 months, and then annually, with physical 
examination every 3 months for 2 years, every 6 months through year 5, and then annually to assess 
tumor status and toxicity. 
Immunohistochemistry  
Tumor tissues were fixed in 10% buffered formalin and embedded in paraffin, according to 
standard procedures. Five-micrometer-thick sections cut from each case were deparaffinized in 
xylene, rehydrated, treated with 0.3% H2O2 in methanol for 10 min to block endogenous peroxidase 
activity, and subjected to heat-induced epitope retrieval in a microwave oven. 
Page 8 of 33
John Wiley & Sons, Inc.
Head & Neck
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rt
ic
le
9 
 
Immunohistochemistry was performed with a Ventana Benchmark XT autostainer according to the 
manufacturer’s instructions (Ventana Medical System, Tucson, AZ). The following primary 
antibodies were used: mouse anti-MCM7 (clone 141.2; dilution 1:100; Santa Cruz Biotechnology, 
Inc., Heidelberg, Germany) and anti-HER1 (clone H11, dilution 1:150, Dako, Milano, Italy) 
monoclonal antibodies; rabbit anti-geminin polyclonal antibody (1:200; Santa Cruz Biotechnology). 
Normal skin and lymph node tissues were used as positive controls for MCM7, HER1 and geminin 
antibodies. Negative controls were performed using non-immunized rabbit and mouse serum, 
omitting the primary antibodies. 
Quantification of immunohistochemical staining. 
Slides were observed with a Zeiss Axioskop 2 microscope and labeling counts for MCM7 and 
geminin antibodies were performed on a monitor, with the aid of a JVC color videocamera. Five 
randomly selected fields, each containing at least 400 tumor cells were counted independently by 
two pathologists and labeling index (LI) for each antibody was calculated as percentage of 
immunostained nuclei. The intensity of HER1 immunohistochemical staining was evaluated using 
image analysis based on Photoshop (AdobeSystems, San Jose, CA) together with ‘The image-
processing toolkit’ (version 3.0, 1998, CRC Press, Boca Raton, FL) according to the method 
previously reported 
27
. Briefly, Tumor tissue was manually selected in digitalized images and the 
integrated density (ID) of the immunostaining was calculated as the product of the mean density 
value of the immunoreactive regions by the percentage of the immunostained tumor tissue. 
The computerised image analysis of all tissue sections were done by three pathologists without 
prior knowledge of the clinical and pathological parameters. 
Statistical analysis 
Survival data was available for all 61 patients. The Cox-Mantel method was used to evaluate the 
prognostic role of MCM7 and geminin as continous variables. For survival analysis, MCM7 and 
geminin continuous variables were converted to binomial variables of high versus low expression 
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around cut-off values chosen on the basis of the results of receiver-operator curve (ROC) analyses 
conducted on the distribution of the LI values of MCM7 (Area under curve = 0.68; CI 95% = 0.56-
0.81; p = 0.02) and geminin ( Area under curve = 0.67; 0.53-0.81; p = 0.02).. Tumors with MCM7 
LI values >50% (43 out of 61) or geminin LI values > 15% (47 out of 61) were considered positive. 
All medians and life tables were computed using the product-limit estimate by Kaplan and Meier 
and and differences among the the Kaplan-Meier estimates were calculated using the log-rank test. 
Reported survival percentages of event-free patients at 5 year follow-up were based on the Kaplan-
Meier estimator. Univariate and multivariate analyses were performed by the Cox proportional 
hazards model. In the the follow-up period (median: 32.1 months; range: 2-139; 95% CI: 25.7-
52.9), the primary and secondary end points went from the beginning of therapy to clinical or 
pathological recurrence (progression-free survival: PFS) and to death (overall survival: OS), 
respectively. All p values were two-sided. Statistical analyses were done by JMP 11 software (SAS 
Institute Inc., Cary, NC). 
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RESULTS 
All LSCC samples showed variable nuclear MCM7 and geminin immunolabeling. No substantial 
labeling for either protein was found in the normal peritumoral tissue, when present. The overall 
mean ± SE of MCM7 and geminin labeling indices (LI) were 68.6% ± 2.7 (median: 65%; range, 15-
100) and 19.4% ± 1.2 (median: 15%; range, 5-60), respectively. No significant correlation between 
MCM7 and geminin LI was observed. 
MCM7 and geminin LI were not associated with age, sex, tumor site, T, stage and nodal status of 
patients while the mean value of MCM7 LI was significantly higher in tumors expressing high 
levels of HER1 (Table 2). 
During the follow-up period (median: 32.1 months; range: 2-139; 95% CI: 25.7-52.9) 30 out of 61 
(49.2%) patients had tumor progression and 10 out of 61 (16.4%) died. 
All the enrolled patients completed the treatment without interruptions.  
MCM7 and geminin LI were first analyzed by Cox regression analysis as continuous variables. 
MCM7 LI values were directly associated with the risk of progression and death. The hazard risk 
ratios were 5.5 (95% C.I.= 1.3-26.4; p = 0.043) and 11.31 (95% C.I.= 0.9-232.2; p = 0.056) for 
progression and death, respectively. Geminin LI values were inversely associated only with the risk 
of progression. The hazard risk ratios were 53.7 (95% C.I.= 2.2-2042.8; p = 0.012). The plots of the 
estimates of survival as a function of MCM7 and geminin levels showed that the increase of MCM7 
LI was associated with a reduction of the progression-free and overall survival fraction of patients 
at 5-year follow-up while the increase of geminin LI was associated with an increased number of 
progression-free patients at 5-year follow-up (Fig 1). 
Kaplan-Meier analyses of survival curves according to MCM7 status showed a significant 
relationship between positive MCM7 LI and short progression-free (log-rank test: p = 0.0005; Fig. 
2A) and overall (log-rank test: p = 0.045 : Fig. 2B) survival. The median PFS was 45 and 26 
months for MCM7 LI <50% and MCM7 LI > 50%, respectively. Kaplan-Meier analysis of survival 
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curves revealed that, at 5 year follow-up, the percentage of progression-free surviving patients with 
MCM7 negative tumors was 86.9% + 8.7 SE while that of progression-free surviving patients with 
MCM7 positive tumors was 24.7% + 10.4 SE. Relative to the overall survival, at 5 year follow-up, 
the percentage of patients still alive was 92.3% + 7.4 SE and 53.4% + 13.7 SE for subjects with 
MCM7 negative and positive tumors, respectively. 
Kaplan-Meier analyses of survival curves according to geminin status showed a significant 
relationship between positive geminin LI and long progression-free survival (log-rank test: p = 
0.0001; Fig. 2C), while no significant association was found between geminin LI and overall 
survival. The median PFS was 33 and 16 months for geminin LI > 15%  and geminin LI < 15%, 
respectively. Kaplan-Meier analyses of survival curves revealed that at 5 year follow-up the 
percentage of progression-free surviving patients with geminin positive tumors was 54.1% + 9.3 SE 
while that of progression-free surviving patients with geminin negative tumors was 0. 
Considering that geminin expression might complement information obtained from MCM7 
labeling, we further examined whether combining MCM7 and geminin status of tumor adds better 
understanding of the prognostic significance of these two proteins. Based on the combined 
expression of MCM7 and geminin, three subpopulations of patients were categorized : MCM7 < 
50% - geminin > 15% (n = 17); MCM7 > 50% - geminin > 15% (n = 31) and MCM7 > 50% - 
geminin < 15% (n = 13). Two illustrative cases are shown in Figure 3: one belonging to the 
subgroup with tumor status MCM7 < 50% - geminin > 15% (A, B) and the other to the subgroup 
with tumor status MCM7 > 50% - geminin < 15% (C, D).  
Kaplan-Meier analyses of survival curves showed a significant relationship between MCM7-
geminin status and progression-free survival (Log-Rank test: p = 0.0001; Fig. 4A) There was no 
significant association with overall survival. Kaplan-Meier analyses of survival curves revealed that 
at 5 year follow-up the percentage of progression-free survival according to MCM7-geminin status 
was: 69.5% + 17.0 SE for MCM7 < 50% - geminin > 15%, 30.4% + 12.8 SE for MCM7 > 50% - 
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geminin > 15%, and 0 for MCM7 > 50% - geminin < 15%.  
Cox’s proportional hazard analysis revealed that, relative to patients with MCM7 < 50% - geminin 
> 15% tumor status, patients with MCM7 > 50% - geminin > 15% and MCM7 > 50% - geminin < 
15% tumor status had a risk of progression 3.1 times (95% C.I. = 1.3-7.2; Likelihood ratio tests: p = 
0.014) and 17.7 times (95% C.I. = 4.7-88.6; Likelihood ratio tests: p = <0.0001) greater, 
respectively. This finding suggests that geminin co-expression can discriminate patients at highest 
risk of progression, among those with MCM7 positive tumors (>50%). 
We then examined whether MCM7-geminin status retains a prognostic value for the duration of 
progression-free survival in the subpopulation of cetuximab treated patients with tumors expressing 
highest levels of HER1. The Survival curves showed a significant relationship between MCM7-
geminin status and progression-free survival also in this patient sub-population (Fig. 4B). Kaplan-
Meier analyses revealed that at 5 year follow-up the proportion of progression-free surviving 
patients according to MCM7-geminin status was: 60.0% + 17 SE for MCM7 < 50% - geminin > 
15%, 28.7% + 12.3 SE for MCM7 > 50% - geminin > 15%, and 0 for MCM7 > 50% - geminin < 
15% (Log-Rank test: p = 0.0002).  
Cox proportional hazard analysis revealed that, relative to patients with MCM7 < 50% - geminin > 
15% tumor status, patients with MCM7 > 50% - geminin > 15% and MCM7 > 50% - geminin < 
15% tumor status had a risk of progression 3.5 times (95% C.I. = 1.3-8.3; Likelihood ratio tests: p = 
0.011) and 17.1 times (95% C.I. = 3.8-124.6; Likelihood ratio tests: p = 0.0001) greater, 
respectively. 
As revealed by univariate analysis cases with transglottic tumor site, high HER1, MCM7 tumor 
expression and low geminin LI were associated with an increased risk of progression while only 
high MCM7 expression was associated with increased risk of death (Table 3). In multivariate 
analysis, the tumor site, MCM7 and geminin LI of tumor retained an indipendent prognostic 
significance relative to the progression-free survival while the age of patient and the MCM7 LI each 
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behaved as an independent prognostic covariate relative to the overall survival (Table 4). Moreover, 
MCM7-geminin status of tumor, when considered, in multivariate analysis, instead of MCM7 and 
geminin covariates separately, showed an independent prognostic significance relative to PFS. 
Patients with MCM7 > 50% - geminin < 15% tumor status had a risk of progression 7.36 higher 
than those with MCM7 > 50% - geminin > 15% tumor status (95% C.I. = 2.5-21.8; Likelihood ratio 
tests: p = <0.0004). Relative to the overall survival, MCM7-geminin status was not considered as 
geminin did not show a significant prognostic role. 
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 DISCUSSION 
MCM7 LI values were directly associated with the risk of progression and death in LSCC patients. 
These findings are consistent with previous studies that have indicated MCM7 as a sensitive 
prognostic marker of various human cancers, including oral squamous cell carcinoma, colorectal 
cancer, ovarian cancer, glioblastoma, and esophageal carcinoma 
6
. Moreover, relative to normal 
epithelium, increased expression of MCM2 has been previously reported in LSCC 
28
. 
MCM7 and geminin LI were not associated with any clinicopathologic parameter and did not 
correlate to each other. The mean value of MCM7 LI, but not geminin, was significantly higher in 
tumors expressing high levels of HER1. This finding could be explained by the recent observation 
that MCM7 binds splicing factor SF3B3 and is essential for splicing of epidermal growth factor 
receptor and other critical growth factor receptor RNAs 
29
. Consequently, the MCM7 RNA splicing 
activity may be exerted through the expression of HER1 and other critical growth factor receptors. 
This suggests that MCM7 has a significant role in producing the pro-growth phenotype that is 
associated with MCM7 overexpression in LSCC. Moreover, it has been recently reported that 
HER1 phosphorylates the p56 isoform of Lyn, which, in turn, phosphorylates MCM7. Activated 
MCM7 then is recruited to the origin of replication complex and initiation of DNA replication 
ensues 
26
. Therefore, MCM7 and HER1 could reinforce the activities of each other in supporting the 
progression of LSCC phenotype. This possibility can be further supported by the finding that the 
activity of Lyn in DNA synthesis and cell proliferation is potentiated in cancer cells whose survival 
depends on EGFR signaling. Furthermore, in this subset of cancer cells, but not in cancer cells less 
growth-dependent on HER1 signaling, a synergistic efficacy of Lyn targeting with EGFR TKIs 
treatment has been documented 
26
. In view of these observations, the finding that MCM7 over-
expression is associated with an adverse clinical outcome in patients with HER1 expressing LSCC, 
provides clinical implications for the treatment of LSCC with deregulated MCM7 status, using 
EGFR and Lyn kinase inhibitors. 
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Geminin LI behaves as a significant predictor of better prognosis in LSCC patients relative to the 
progression-free survival. Our data are in agreement with previous reports in patients with oral 
squamous cell carcinoma 
30
 and high-grade astrocytic brain tumors 
31
 where high geminin 
expression is a significant predictor of better prognosis. However, in patients with breast 
32
, renal 
33
 
and colorectal cancer 
34
 geminin over-expression has been associated with poor prognosis and the 
frequent overexpression in tumor cells together with the ability to stimulate cell cycle progression 
and proliferation have supported its role of a classical oncogene.  
Our results in LSCC patients are inconsistent with the oncogenic role attributed to geminin. 
However, the favorable prognostic role of geminin can be explained considering that the elevated 
levels of geminin could indicate the chemo-radio sensitivity of LSCC. 
This possibility was supported by the observation that high levels of geminin expression promote 
G1 to S progression and accumulation of cancer cells in the S-G2-M phase of the cell cycle 
35
 
where they are most chemo-radio sensitive. On the other hand, a significant reduction of geminin 
expression was observed after chemo-radio treatment in primary rectal cancers containing high 
levels of geminin 
35
, further suggesting that cells expressing high levels of geminin might be more 
susceptible to chemo–radio treatment. Then, evaluation of geminin expression might serve as a 
prognostic marker of response to chemo–radio therapy in LSCC patients. This possibility is also in 
agreement with what was observed in patients with oral squamous cell carcinoma 
30
 and high-grade 
astrocytic brain tumors 
31
 who have undergone chemo-radio treatment. 
Geminin expression, as a prognostic marker of response to chemo–radio therapy, complements the 
prognostic informations obtained from MCM7 expression in tumor cells. In fact, patients with 
LSCC containing high levels of MCM7 had a significantly reduced risk of progression when their 
cancer cells also expressed high levels of geminin. Furthermore, the MCM7-geminin status of the 
tumor behaves as a prognostic marker independent from the expression levels of HER1 and, then, it 
seems to improve the prognostic role of the HER1 expression, identifying a subgroup of patients 
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with different local response to radiotherapy and biotherapy. All the patients in the present study 
were treated by the combination of cetuximab with radiotherapy, for whom HER1 expression does 
not seem to act as a reliable predictor of the response, and does not help in treatment selection. 
MCM7-geminin status, which is a downstream marker of EGFR pathway, may on the other hand 
reveal very useful for this aim and be employed in the clinical practice for the selection of patients 
to submit to concurrent treatment with c225 or other anti-EGFR drugs instead of the other standard 
drug for concomitant RTCT in the head and neck which is cisplatin. 
In conclusion, to the best our knowledge, this is the first study demonstrating that MCM7-geminin 
status is a reliable independent prognostic marker of the clinical outcome in LSCC patients. A well-
designed, prospective, randomized multi-institutional study with a higher number of patients and a 
longer follow-up is needed to confirm our preliminary results. In fact, if the MCM7–geminin 
prognostic role was validated on independent cohorts, their gene expression patterns may provide 
valuable information that can be used to assist in treatment decisions for HNSCC. 
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FIGURE LEGENDS 
 
Figure 1. Plots of the estimates of progression-free and overall survival as a function of MCM7 
LI (A) and geminin LI (B) values. The proportional hazards model was evaluated at each 
covariate value and the proportion of patients without event at 5-year follow-up was estimated 
from the computed survival functions. 
 
Figure 2. Kaplan-Meier analysis of survival curves as a function of MCM7 (A, B) and geminin 
(C) status of tumor in laryngeal squamous carcinoma patients. Cut-off values of the variables 
were chosen according to the results of ROC curve analyses. The median progression-free 
survival were 26  and 45 months for MCM7 LI > 50% and < 50%, respectively and 33 and 16 
months for geminin LI > 15% and < 15%, respectively. The median overall survival for MCM7  
LI > 50% was 27 months while that for MCM7 LI < 50% was undefinied. 
 
Figure 3. Immunohistochemical analysis of two illustrative cases of laryngeal squamous 
carcinoma: one expressing low MCM7 (A) and high geminin (B) LI and the other showing high 
MCM7 (C) and low geminin (D) LI. Bar = 50x. 
 
Figure 4. Kaplan-Meier analysis of progression-free survival curves as a function of MCM7- 
geminin status of tumor in the overall patient population (A) and in the subpopulation of patients 
with tumors expressing high levels of HER1 (B). 
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Table 1. Descriptive statistics of the main variables concerning patients and tumour parameters.  
Characteristic 61 patients 
Age at diagnosis 
Median 
Range 
 
65 
40-86 
Sex-no. (%) 
Male 
Female 
 
55 (90.2%) 
6 (9.8%) 
Smoking Status 
Smokers 
Non Smokers 
Unknown status 
 
22 (36,1%) 
29 (47.5%) 
10 (16.4%) 
Drinking Status 
Drinkers 
Non Drinkers 
Previous Drinkers 
 
30 (49.2%) 
24 (39.3%) 
7 (11.5%) 
Follow-up period in months 
Median 
Range 
 
32.1 months 
2-139 months 
Subsite 
Supraglottic 
Glottic 
Transglottic 
 
25 (41%) 
20 (32,8%) 
16 (26.2%) 
T 
T2 
T3-4 
 
33 (54%) 
28 (46%) 
N 
Negative 
 
44 (72.1%) 
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Positive 17 (27.9%) 
Stage 
1-2 
3-4 
 
26 (42.6%) 
35 (57.4%) 
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Table 2. MCM7 and Geminin  labeling indices according to clinico-pathological characteristics of 
61 laryngeal squamous carcinoma patients. 
           MCM7      p
1
             GEMININ      p 
 AGE   N     (mean + SE)             N     (mean + SE) 
    < 60  17      63.9
2
 + 5.5   17     18.5 + 2.3 
    > 60 44      67.5 +  3.3    0.64  44     19.9 + 1.4    0.57 
SEX 
   female        6      59.3 + 10.2     6     18.3 + 3.8 
   male           55     67.6 + 2.9    0.29  55     19.6 + 1.3    0.86 
TUMOR SITE 
  supraglottic  25     67.5 + 4.8                       25    19.5 + 1.8 
  glottic   20     63.0 + 4.7                        20    19.2 + 1.5 
  transglottic 16      70.3 + 4.9    0.45  16     19.6 + 3.1    0.74 
T 
   2   33     68.9 + 3.5                       33     18.8 + 1.8 
   3-4   28     64.2 + 4.5    0.28         28     19.6 + 1.5    0.16 
STAGE  
   1-2  26     67.0 + 3.9      26     18.6 + 2.2  
   3-4  35     66.3 + 4.0        0.86   35     19.6 + 1.3    0.15 
NODAL STATUS 
  negative 44     65.0 + 3.3     44     18.5 + 1.5 
  positive 17     71.1 + 5.5        0.21     17     20.9 + 1.9    0.20 
HER1 
   < 14 I.D.3 11     48.7 + 6.2               11    21.3 + 2.7 
   > 14 I.D.     50     71.2 + 2.9        0.003    50    18.8 + 1.3    0.38 
1)
 Wilcoxon  test; 
2)
Labeling index; 
3)
Integrated density. 
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Table 3. Univariate analysis of prognostic covariates in laryngeal squamous cancer patients. 
 
       RELAPSE-FREE SURVIVAL               OVERALL SURVIVAL 
            
                      N     R.R. (C.I. 95%)      p
1
               N     R.R. (C.I. 95%)        p 
AGE  
> 60                44     1
2
     44     1 
< 60                17     1.15 (0.5-2.6)      0.74   17     4.10 (1.2-16.1)      0.028 
SEX 
female              6     1       6     1 
male               55     4.15   (0.9-74.1)     0.08  55     1.15 (0.2-21.3)      0.89 
T classification 
2                     32      1     32     1 
3-4                 29      0.98 (0.5-2.1)       0.96  29     1.03 (0.3-4.2)       0.97  
STAGE 
1-2                 26      1     26     1 
3-4                 35       0.74 (0.6-2.8)      0.43  35     1.22 (0.3-5.8)      0.77 
TUMOR SITE 
supraglottic / 
glottic  45       1      45     1 
transglottic    16       3.72 (1.6-8.3)       0.0023    16     2.48 (0.5-9.3)      0.23 
NODAL STATUS 
 negative        44       1     44     1 
 positive         17       0.87 (0.3-1.9)        0.75  17     2.81 (0.7-10.7)      0.14 
HER1 
 < 14 I.D.       11       1     11     1 
 > 14 I.D.       50       4.67 (1.4-29.0)     0.009   50     2.70 (0.5-49.5)      0.29 
MCM7 
  < 50%          18      1     18     1         
  > 50%          43      5.15 (1.9-18.2)    0.0007  43     7.01 (1.3-130.1)      0.021 
GEMININ  
  > 15%         30      1      30     1     
  < 15%         31      4.60 (1.9-10.6)     0.0012   31     1.23 (0.1-15.7)      0.85 
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1) Likelihood ratio tests; 
2)
Reference risk.  
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Table 4. Mulivariate analysis of prognostic covariates in laryngeal squamous cancer 
patients. 
 
       RELAPSE-FREE SURVIVAL               OVERALL SURVIVAL 
            
                      N     R.R. (C.I. 95%)        p
1
               N     R.R. (C.I. 95%)            p 
AGE  
> 60                44     1
2
     44     1 
< 60                17     1.47 (0.5-3.9)        0.45  17   57.37  (4.0-1927.5)      0.001 
SEX 
female              6     1       6     1 
male               55     2.02  (0.3-38.6)      0.48  55     0.10   (0.02-4.2)          0.20 
T classification 
2                     32      1     32     1 
3-4                  29      2.95 (0.5-11.7)      0.29  29     1.34   (0.06-17.3)         0.82  
STAGE 
1-2                 26      1     26     1 
3-4                 35       0.33 (0.5-2.0)        0.23  35     0.47   (0.01-13.5)         0.67 
TUMOR SITE 
supraglottic / 
glottic  45       1      45     1 
transglottic    16       2.96 (1.1-7.8)         0.028    16   11.42   (0.8-219.8)        0.07 
NODAL STATUS 
 negative        44       1     44     1   
 positive         17       1.34 (0.4-4.6)         0.65  17     2.29     (0.2-28.6)         0.51 
HER1 
 < 14 I.D.       11       1     11     1 
 > 14 I.D.       50       1.78 (0.6-6.3)        0.31   50     1.34     (0.05-72.5)       0.86 
MCM7 
  < 50%          18      1     18     1         
  > 50%          43      3.90 (1.2-16.3)        0.02  43     6.17      (0.9-67.8)       0.04 
GEMININ  
  > 15%         30      1      30     1     
  < 15%         31      7.36 (2.5-21.8)         0.004   31     4.44    (0.1-224.7)      0.40 
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1) Likelihood ratio tests; 
2)
Reference risk. 
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Plots of the estimates of progression-free and overall survival as a function of MCM7 LI (A) and geminin LI 
(B) values. The proportional hazards model was evaluated at each covariate value and the proportion of 
patients without event at 5-year follow-up was estimated from the computed survival functions.  
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Kaplan-Meier analysis of survival curves as a function of MCM7 (A, B) and geminin (C) status of tumor in 
laryngeal squamous carcinoma patients. Cut-off values of the variables were chosen according to the results 
of ROC curve analyses. The median progression-free survival were 26  and 45 months for MCM7 LI > 50% 
and < 50%, respectively and 33 and 16 months for geminin LI > 15% and < 15%, respectively. The median 
overall survival for MCM7  LI > 50% was 27 months while that for MCM7 LI < 50% was undefinied.  
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Immunohistochemical analysis of two illustrative cases of laryngeal squamous carcinoma: one expressing 
low MCM7 (A) and high geminin (B) LI and the other showing high MCM7 (C) and low geminin (D) LI. Bar = 
50x.  
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Kaplan-Meier analysis of progression-free survival curves as a function of MCM7- geminin status of tumor in 
the overall patient population (A) and in the subpopulation of patients with tumors expressing high levels of 
HER1 (B).  
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